Étiquette : adverse effects

Cannabis use and mental health : risks and benefits, Wayne HALL et al., 2019

Cannabis use and mental health: risks and benefits Wayne HALL, · Eva HOCH, · Valentina LORENZETTI European Archives of Psychiatry and Clinical Neuroscience, february 2019 https://doi.org/10.1007/s00406-019-00986-2 © Springer-Verlag GmbH Germany, part of Springer Nature 2019   In public debates about cannabis policy, two competing claims are often made about how cannabis use may affect mental health. One is that cannabis use by young adults and vulnerable individuals across the lifespan can be a contributory cause of : a cannabis dependence syndrome; schizophreniform psychoses; anxiety and depressive disorders; acute and perhaps chronic cognitive impairment, and structural and functional changes in brain pathways implicated in reward, learning and [...]

Lire la suite

Marijuana, National Institute on Drug Abuse (NIDA), June 2018

Marijuana, National Institute on Drug Abuse (NIDA), June 2018 Table of Contents Marijuana Letter From the Director What is marijuana? What is the scope of marijuana use in the United States? What are marijuana effects? How does marijuana produce its effects? Does marijuana use affect driving? Is marijuana addictive? What are marijuana's long-term effects on the brain? Is marijuana a gateway drug? How does marijuana use affect school, work, and social life? Is there a link between marijuana use and psychiatric disorders? What are marijuana's effects on lung health? What are marijuana’s effects on other aspects of physical health? Is marijuana safe and effective as medicine? What are the effects of secondhand exposure to marijuana smoke? Can marijuana [...]

Lire la suite

Medicinal cannabis : History, Pharmacology and Implication for the Acute Care Settings, M. Barna Bridgeman, D.T. Abazia, Pharmacy & Therapeutics, 2017, 42, 3,180-188.

Medicinal cannabis : History, Pharmacology and Implication for the Acute Care Settings Mary Barna Bridgeman, PharmD, BCPS, BCGP; and Daniel T. Abazia, PharmD, BCPS, CPE Pharmacy & Therapeutics®, 2017 • Vol. 42 No. 3, pp 180-188.   INTRODUCTION Medicinal cannabis, or medicinal marijuana, is a therapy that has garnered much national attention in recent years. Controversies surrounding legal, ethical, and societal implications associated with use; safe administration, packaging, and dispensing; adverse health consequences and deaths attributed to marijuana intoxication; and therapeutic indications based on limited clinical data represent some of the complexities associated with this treatment. Marijuana is currently recognized by the U.S. Drug Enforcement Agency’s [...]

Lire la suite

La Réduction des Méfaits de la Consommation de Cannabis à des Fins Non Médicales, Association des Infirmières et Infirmiers du Canada, janvier 2018

La Réduction des Méfaits de la Consommation de Cannabis à des Fins Non Médicales Association des Infirmières et Infirmiers du Canada, janvier 2018, 18 pp. Ottawa, Ontario, Canada.   https://www.cna-aiic.ca/~/media/cna/page-content/pdf-fr/la-reduction-des-mefaits-de-la-consommation-de-cannabis-a-des-fins-non-medicales.pdf?la=fr  

Lire la suite

Les méta-analyses et le cannabis, ou la négation du savoir clinique, 21 Septembre 2011, Dr. Christian Sueur,

Les méta-analyses et le cannabis, ou la négation du savoir clinique 21 Septembre 2011 Dr. Christian Sueur, Psychiatre, praticien hospitalier http://tdme.free.fr/?p=2730#annot8   A l’ère des méta-analyses, la clinique psychiatrique bat de l’aile…., Ce que l’on peut lire aujourd’hui sur les « dangers du cannabis » fournit un exemple étonnant de cette perte du savoir clinique. Et pourtant, bien des « méta-analystes » qui parfois, n’ont jamais vu un patient, sans vergogne, « disent le vrai », et emportent l’opinion avec eux, opinion et journalistes qui se font l’écho de ses assertions, sans même émettre la moindre critique vis-à-vis de ces « chiffres » érigés en « [...]

Lire la suite

Adverse effects of medical cannabinoids : a systematic review, T. Wang et al., 2008

Adverse effects of medical cannabinoids : a systematic review T. Wang, J-P. Collet, S. Shapiro, M.A. Ware, Canadian Medical Association Journal, 2008,178,13, 1669-1678 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2413308/pdf/20080617s00017p1669.pdf   Abstract Background : The therapeutic use of cannabis and cannabisbased medicines raises safety concerns for patients, clinicians, policy-makers, insurers, researchers and regulators. Although the efficacy of cannabinoids is being increasingly demonstrated in randomized controlled trials, most safety information comes from studies of recreational use. Methods : We performed a systematic review of safety studies of medical cannabinoids published over the past 40 years to create an evidence base for cannabis-related adverse events and to facilitate future cannabis research initiatives. We critically evaluated [...]

Lire la suite

Medical Consequences of Cannabis Use , Jag H. Khalsa and Ruben Baler, janvier 2019

Medical Consequences of Cannabis Use Jag H. Khalsa, MS, PhD and Ruben Baler, PhD   National Institute on Drug Abuse, National Institutes of Health, Bethesda,   Janvier 2019   Disclaimer: The opinions in this paper are of authors and do not reflect the position of the National Institute on Drug Abuse, National Institutes of Health. Abstract Consumed by an estimated 2.5% of the world’s population, cannabis is the most popular illicit drug. Depending on age of onset, frequency, duration, and other variables, cannabis use can be associated with a broad spectrum of medical consequences, the range of which mirrors the physiological ubiquity and versatility of the endocannabinoid [...]

Lire la suite